» Articles » PMID: 33419403

Thyroid Cancer Overdiagnosis and Overtreatment: a Cross- Sectional Study at a Thyroid Cancer Referral Center in Ecuador

Abstract

Background: In contrast to the rapid increase in thyroid cancer incidence, the mortality has remained low and stable over the last decades. In Ecuador, however, thyroid cancer mortality has increased. The objective of this study is to determine possible drivers of high rates of thyroid cancer mortality, through a cross-sectional analysis of all patients attending a thyroid cancer referral center in Ecuador.

Methods: From June 2014 to December 2017, a cross-sectional study was conducted at the Hospital de Especialidades Eugenio Espejo, a regional reference public hospital for endocrine neoplasia in adults in Quito, Ecuador. We identified the mechanism of detection, histopathology and treatment modalities from a patient interview and review of clinical records.

Results: Among 452 patients, 74.8% were young adults and 94.2% (426) were female. 13.7% had a family history of thyroid cancer, and patients' median tumor size was 2 cm. The incidental finding was 54.2% whereas 45.8% was non-incidental. Thyroid cancer histology reported that 93.3% had papillary thyroid cancer (PTC), 2.7% follicular, 1.5% Hurtle cells, 1.6% medullary, 0.7% poor differentiated, and 0.2% anaplastic carcinoma. The mean MACIS (metastasis, age, completeness, invasion, and size) score was 4.95 (CI 4.15-5.95) with 76.2% of the thyroid cancer patients having MACIS score less than or equal to 6. The very low and low risk of recurrence was 18.1% (79) and 62% (271) respectively. An analysis of 319 patients with non-metastatic thyroid cancer showed that 10.7% (34) of patients had surgical complications. Moreover, around 62.5% (80 from 128 patients with thyroglobulin laboratory results) of TC patients had a stimulated-thyroglobulin value equal or higher than 2 ng/ml. Overall, a poor surgical outcome was present in 35.1% (112) patients. Out of 436 patients with differentiated thyroid carcinoma, 86% (375) received radioactive iodine.

Conclusion: Thyroid cancer histological characteristics and method of diagnosis are like those described in other reports without any evidence of the high frequency of aggressive thyroid cancer histology. However, we observed evidence of overtreatment and poor surgical outcomes that demand additional studies to understand their association with thyroid cancer mortality in Ecuador.

Citing Articles

How Many Lymph Nodes are Enough in Thyroidectomy? A Cohort Study Based on Real-World Data.

Wei B, Tan H, Chen L, Chang S, Wang W Ann Surg Oncol. 2024; 32(2):1149-1157.

PMID: 39521741 DOI: 10.1245/s10434-024-16391-6.


Prognostic nomogram models for elderly patients with differentiated thyroid carcinoma: A population-based study.

Wang D, Yang Y, Yang H, He Y, Wang Z, Chen M Medicine (Baltimore). 2024; 103(44):e40381.

PMID: 39496024 PMC: 11537660. DOI: 10.1097/MD.0000000000040381.


Characteristics and survival of adults with differentiated thyroid cancer in a Peruvian hospital.

Morales-Concha L, Huamani-Linares I, Saihua-Palomino K, Luque Florez E, Chavez Echevarria A, Tupayachi Palomino R Rev Peru Med Exp Salud Publica. 2024; 41(3):287-293.

PMID: 39442111 PMC: 11495931. DOI: 10.17843/rpmesp.2024.413.13378.


Nomogram for predicting the risk of central lymph node metastasis in papillary thyroid microcarcinoma: a combination of sonographic findings and clinical factors.

Duan S, Yang Z, Wei G, Chen S, Hu X, Ryu Y Gland Surg. 2024; 13(6):1016-1030.

PMID: 39015718 PMC: 11247594. DOI: 10.21037/gs-24-154.


Thyroid cancer in Ecuador: A genetic variants review and a cross-sectional population-based analysis before and after COVID-19 pandemic.

Paz-Cruz E, Cadena-Ullauri S, Guevara-Ramirez P, Ruiz-Pozo V, Tamayo-Trujillo R, Simancas-Racines D Heliyon. 2024; 10(1):e23964.

PMID: 38226262 PMC: 10788530. DOI: 10.1016/j.heliyon.2023.e23964.


References
1.
Chang Y, Kim H, Jung S, Kim H, Lee J, Bae J . Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. Int J Clin Oncol. 2016; 21(5):862-868. DOI: 10.1007/s10147-016-0956-2. View

2.
Haugen B . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer. 2016; 123(3):372-381. DOI: 10.1002/cncr.30360. View

3.
Al-Ammar Y, Al-Mansour B, Al-Rashood O, Tunio M, Islam T, Al-Asiri M . Impact of body mass index on survival outcome in patients with differentiated thyroid cancer. Braz J Otorhinolaryngol. 2017; 84(2):220-226. PMC: 9449218. DOI: 10.1016/j.bjorl.2017.02.002. View

4.
Lamartina L, Grani G, Durante C, Borget I, Filetti S, Schlumberger M . Follow-up of differentiated thyroid cancer - what should (and what should not) be done. Nat Rev Endocrinol. 2018; 14(9):538-551. DOI: 10.1038/s41574-018-0068-3. View

5.
Li M, Dal Maso L, Vaccarella S . Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020; 8(6):468-470. DOI: 10.1016/S2213-8587(20)30115-7. View